[1]庞 欢,尹倩雯,王晓岩,等.奥森多VITROS4600全自动生化分析仪检测血清酶类项目应用不同稀释基质对其临床可报告范围的影响评估[J].现代检验医学杂志,2026,41(03):28-33.[doi:10.3969/j.issn.1671-7414.2026.03.005]
　PANG Huan,YIN Qianwen,WANG Xiaoyan,et al.Evaluation of the Impact of Different Diluent Matrices on the Clinical Reportable Range of Serum Enzyme Items Detected by Ortho VITROS 4600 Automated Biochemical Analyzer[J].Journal of Modern Laboratory Medicine,2026,41(03):28-33.[doi:10.3969/j.issn.1671-7414.2026.03.005]
点击复制

奥森多VITROS4600全自动生化分析仪检测血清酶类项目应用不同稀释基质对其临床可报告范围的影响评估()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年03期
页码:
28-33
栏目:
论著
出版日期:
2026-05-13

文章信息/Info

Title:
Evaluation of the Impact of Different Diluent Matrices on the Clinical Reportable Range of Serum Enzyme Items Detected by Ortho VITROS 4600 Automated Biochemical Analyzer
文章编号:
1671-7414（2026）03-028-06
作者:
庞 欢，尹倩雯，王晓岩，阮竞雄，王晓琴
西安交通大学第一附属医院检验科，西安 710061
Author(s):
PANG Huan，YIN Qianwen，WANG Xiaoyan，RUAN Jingxiong，WANG Xiaoqin
Department of Clinical Laboratory, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
关键词:
血清酶; 稀释基质; 干化学; 临床可报告范围; 最大稀释度
分类号:
R392-33；R446.1
DOI:
10.3969/j.issn.1671-7414.2026.03.005
文献标志码:
A
摘要:
目的评价不同稀释基质对奥森多VITROS4600全自动生化分析仪检测血清酶（ALT、AST、ALP、LDH、CK、CK-MB、AMY、LIPA）最大稀释倍数的影响，旨在确定最适宜的稀释基质，并制定基质特异性临床可报告范围（CRR）。方法依据中国合格评定国家认可委员会（CNAS）-GL037：2019《临床化学定量检验程序性能验证指南》，验证ALT、AST、ALP、LDH、CK、CK-MB、AMY和LIPA的分析测量范围（AMR）。选取去离子水、生理盐水、7g/dl小牛血清白蛋白（BSA）及加工人血清作为稀释基质，分别进行最大稀释倍数验证，建立不同稀释基质下的临床可报告范围。结果ALT的线性范围为10～697U/L，r2=0.999，去离子水稀释时最大稀释倍数最高为20倍；AST的线性范围为12～716U/L，r2=0.995，7g/dlBSA稀释时最大稀释倍数最高为20倍；ALP的线性范围为22～1204U/L，r2=0.998，7g/dlBSA稀释时最大稀释倍数最高为10倍；LDH的线性范围为137～946U/L，r2=0.999，7g/dlBSA稀释时最大稀释倍数最高为10倍；CK的线性范围为24～1489U/L，r2=0.998，四种基质稀释后的偏倚均大于行业规定；CK-MB的线性范围为4.7～283.1U/L，r2=0.999，加工人血清稀释时最大稀释倍数最高为20倍；AMY的线性范围为45～1162U/L，r2=0.999，去离子水稀释时最大稀释倍数最高为15倍；LIPA的线性范围为23～1793U/L，r2=0.999，加工人血清稀释时最大稀释倍数最高为20倍。结论不同血清酶项目在不同稀释基质中的稀释结果存在差异，需要建立基质特异性临床可报告范围。
Abstract:
Objective To evaluate the impact of different dilution matrices on the maximum dilution factors for the detection of serum enzymes (ALT, AST, ALP, LDH, CK, CK-MB, AMY, LIPA) using the Ortho VITROS 4600 fully automated biochemical analyzer, aiming to determine the most suitable dilution matrix and establish the matrix-specific clinical reportable ranges (CRR). Methods According to the China National Accreclitation Service for Conformity Assessment (CNAS)-GL037:2019 “Guidance on the Verification of Quantitative Measurement Procedures used in the Clinical Chemistry”, the analytical measurement ranges (AMR) for ALT, AST, ALP, LDH, CK, CK-MB, AMY and LIPA were validated. Deionized water, physiological saline, 7g/dl bo-vine serum albumin (BSA), and processed human serum were selected as dilution matrices. Maximum dilution factor validation was performed for each matrix to establish CRR under different dilution conditions. Results The linear range for ALT was 10-697 U/L, with an r2 of 0.999. The maximum dilution factor was 20-fold when diluted with deionized water. For AST verification, the linear range was 12~716 U/L, with an r2 of 0.995. The maximum dilution factor was 20-fold when diluted with 7g/dl BSA. The linear range for ALP was 22~1 204 U/L, with an r2 of 0.998. The maximum dilution factor was 10-fold when diluted with 7g/dl BSA. LDH showed a linear range of 137~946 U/L, with an r2 of 0.999. The maximum dilution factor was 10-fold when di-luted with 7g/dl BSA. CK had a linear range of 24~1 489 U/L, with an r2 of 0.998, and the biases for all four diluted substrates exceeded industry standards. The linear range for CK-MB was 4.7~283.1 U/L, with an r2 of 0.999. The maximum dilution fac-tor was 20-fold when diluted with processed human serum. AMY showed a linear range of 45~1 162 U/L, with an r2 of 0.999.The maximum dilution factor was 15-fold when diluted in deionized water. LIPA had a linear range of 23~1 793 U/L, with an r2 of 0.999. The maximum dilution factor was 20-fold when diluted in processed human serum. Conclusions The dilution results vary across differ-ent serum enzyme assays in different dilution matrices, necessitating the establishment of matrix-specific CRR.

参考文献/References:

[1] 顾益凤,张小霞,张敏,等. 不同稀释介质对化学发光免疫法检测血清游离前列腺特异性抗原结果的评估[J].现代检验医学杂志, 2022, 37(2): 157-161. GU Y F, ZHANG X X, ZHANG M, et al. Result evalu-ation of serum free prostate specific antigen by chemi-luminescence immunomethods in different dilution me-dia [J]. Journal of Modern Laboratory Medicine, 2022, 37(2): 157-161.
[2] 中国合格评定国家认可委员会.CNAS-GL037:临床化学定量检验程序性能验证指南[EB/OL]. (2019-02-15)https://www.cnas.org.cn/cms_files/filemanager/328304128/attach/202412/8FC9EF-563658C7AAE38FCFFFA97A7AF7.pdf. China National Accreditation Service for Conformity Assessment.CNAS-GL037: Guidance on the verifica-tion of quantitative measurement procedures used in the clinical chemistry[EB/OL]. (2019-02-15)https://www.cnas.org.cn/cms_files/filemanager/328304128/attach/202412/8FC9EF563658C7AAE38FCFF-FA97A7AF7.pdf.
[3] 中华人民共和国国家卫生健康委员会.WS/T 403-2024:临床化学检验常用项目分析质量标准[EB/OL]. (2024-05-09)[2024-11-01]https://www.nhc.gov. cn/cms-search/downFiles/8c6c3e140f54489384ec-c63706ce859b.pdf. National Health Commission of the People’s Republic of China. WS/T 403-2024: Analytical performance standard for routine analytes in clinical chemistry[EB/OL]. (2024-05-09)[2024-11-01]https://www.nhc.gov. cn/cms-search/downFiles/8c6c3e140f54489384ec-c63706ce859b.pdf.
[4] 赵巧燕,颜巍.罗氏Cobas 8000全自动生化分析仪检测系统性能验证[J].检验医学与临床, 2020, 17(23):3425-3428. ZHAO Q Y, YAN W. Testing system performance ver-ification of Roche Cobas 8000 automatic biochemical analyzer[J]. Laboratory Medicine and Clinic, 2020, 17(23): 3425-3428.
[5] 唐红辉,李洪春.基于吖啶酯化学发光免疫定量分析技术建立血清IL-6水平检测方法与初步应用评价[J].现代检验医学杂志, 2024, 39(4): 175-179, 185. TANG H H, LI H C. Establishment of the detection method of serum IL-6 level and its preliminary appli-cation evaluation based on acridine ester chemilumi-nescence immune quantitative analysis technology[J]. Journal of Modern Laboratory Medicine, 2024, 39(4):175-179, 185.
[6] 夏曦,张林元,周文中.Atellica IM1600检测国产甲状腺激素相关试剂性能验证[J].标记免疫分析与临床, 2025, 32(6): 1255-1263, 1311. XIA X, ZHANG L Y, ZHOU W Z. A performance study of Atellica IM1600 detection of domestic thyroid hormone-related reagents[J]. Labeled Immunoassays and Clinical Medicine, 2025, 32(6): 1255-1263, 1311.
[7] 姚少羽,孙艳虹,高玲,等.Vitros950生化检测系统最大稀释度测定[J].中国实用医药,2008,3(34):31-34. YAO S Y, SUN Y H, GAO L, et al. Determination of the maximum dilution in Vitros 950 biochemistry sys-tem[J]. China Practical Medical, 2008, 3(34): 31-34.
[8] 颜绵生,高玲,姚真荣,等.干化学淀粉酶?脂肪酶的临床可报告范围研究[J].热带医学杂志, 2011, 11(6):650-652. YAN M S, GAO L, YAO Z R, et al. Determining the clinical report range AMYL and LIPA in dry chemis-try[J]. Journal of Tropical Medicine, 2011, 11(6): 650-652.
[9] KHAN A R , JAVAID F , ALTAF S ,et al.Cardio-he-patic interactions in acute heart failure A study on liver function test abnormalities[J].Annals of King Edward Medical University, 2025, 31(1):46.
[10] 杨春旺,王令红,陶珊珊,等.NSTEMI患者血流储备分数与心肌酶谱间的关系及对主要不良心血管事件的预测价值[J].中国动脉硬化杂志, 2023, 31(3):253-260. YANG C W, WANG L H, TAO S S, et al. The relation-ship between fractional flow reserve and myocardial zymogram in patients with NSTEMI and its predictive value for major adverse cardiovascular events[J]. Chi-nese Journal of Arteriosclerosis, 2023, 31(3): 253-260.
[11] 中华医学会外科学分会胰腺外科学组.中国急性胰腺炎诊治指南(2021)[J].中华外科杂志,2021,59(7):578-587. Chinese Pancreatic Surgery Association,Chinese Society of Surgery,Chinese Medical Association. Guidelines for diag-nosis and treatment of acute pancreatitis in China(2021) [J]. Chinese Journal of Surgery, 2021, 59(7): 578-587.
[12] 张旭东,刘永革,任亦欣,等.儿童总免疫球蛋白E和特异性免疫球蛋白E临床可报告范围建立的研究[J].标记免疫分析与临床, 2022, 29(5): 852-856. ZHANG X D, LIU Y G, REN Y X, et al. A study of establishing the clinical reportable range of total immu-noglobulin E and specific immunoglobulin E in chil-dren[J]. Labeled Immunoassays and Clinical Medicine,2022, 29(5): 852-856.
[13] PFLEGER C, SCHLOOT N, TER VELD F. Effect of serum content and diluent selection on assay sensitivity and signal intensity in multiplex bead-based immuno-assays[J]. Journal of Immunological Methods, 2008, 329(1/2): 214-218.
[14] 叶桂样,黄瑞勋,卓雪芽,等.干片式生化仪校准品基质效应研究[J].检验医学与临床, 2015, 12(22): 3329-3331. YE G Y, HUANG R X, ZHUO X Y, et al. Study on matrix effect of calibrator of dry type biochemical ana-lyzer[J]. Laboratory Medicine and Clinic, 2015, 12(22):3329-3331.
[15] 无琼,禹松林,国秀芝,等.不同稀释介质对抗甲状腺球蛋白抗体稀释测定的影响[J].中华检验医学杂志,2018,41(11):875-878. WU Q, YU S L, GUO X Z, et al. Effect of different dilution media on the determination of thyroglobulin antibody dilution[J]. Chinese Journal of Laboratory Medicine, 2018, 41(11): 875-878.
[16] 范金斌,仲远,张统一.不同浓度低值血清稀释生化项目结果的差异性[J].医学检验与临床,2022,33(2):60-62, 82. FAN J B, ZHONG Y, ZHANG T Y. The variations in biochemical test results observed with different low-concentration serum dilutions[J]. Medical Labora-tory Science and Clinics, 2022, 33(2): 60-62, 82.
[17] 罗中兰,王丽馨,杨沛,等.强生VITROS5.1FS生化分析仪6个血清酶项目的可报告范围验证[J].国际检验医学杂志, 2017, 38(4): 528-530. LUO Z L, WANG L X, YANG P, et al. Validation of the reporting range for six serum enzyme items of the Johnson&Johnson VITROS 5.1FS biochemical ana-lyzer[J]. International Journal of Laboratory Medicine, 2017, 38(4): 528-530.

备注/Memo

备注/Memo:
基金项目：西安市重点产业链技术攻关集群项目（24LLRHZDZX0028）。
作者简介：庞欢（1989-），女，硕士，主管检验师，主要从事临床检验诊断，E-mail：ph20241023@163.com。
通讯作者：王晓琴（1971-），女，博士，主任技师，主要从事肿瘤、免疫、分子和病原学诊断，E-mail：wxq1493722680@xjtufh.edu.cn。
更新日期/Last Update: 2026-05-15